RADIUM REVISITED: CLINICAL EXPERIENCES WITH A NOVEL ALPHA-EMITTING BONE-SEEKING RADIOPHARMACEUTICAL IN PATIENTS WITH SKELETAL METASTASES FROM PROSTATE AND BREAST CANCER

被引：0
|
作者：
Nilsson, S. [1 ]
Larsen, R. H. [2 ]
Bruland, O. S. [3 ]
机构：
[1] Karolinska Hosp, S-10401 Stockholm, Sweden
[2] Algeta Inc, Oslo, Norway
[3] Norwegian Radium Hosp, Oslo, Norway
来源：
ANTICANCER RESEARCH | 2004年 / 24卷 / 5D期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3445 / 3446
页数：2
相关论文
共 50 条
  • [31] Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer
    Francesca Pons
    Ramón Herranz
    Alicia Garcia
    Sergi Vidal-Sicart
    Carles Conill
    Juan José Grau
    Joan Alcover
    David Fuster
    Jordi Setoain
    European Journal of Nuclear Medicine, 1997, 24 : 1210 - 1214
  • [32] The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer
    Hadji, Peyman
    Ziller, May
    Maurer, Tobias
    Autenrieth, Michael
    Muth, Mathias
    Ruebel, Amelie
    May, Christoph
    Birkholz, Katrin
    Diebel, Erhardt
    Gleissner, Jochen
    Rothe, Peter
    Gschwend, Juergen E.
    JOURNAL OF BONE ONCOLOGY, 2012, 1 (03) : 88 - 94
  • [33] Clinical benefit of routine application of Rhenium-188-HEDP in patients with painful bone metastases from prostate or breast cancer
    Lange, R.
    Overbeek, F.
    van den Berk, A. M.
    de Klerk, J. M. H.
    Pasker-de Jong, P. C. M.
    ter Heine, R.
    van der Westerlaken, M. M. L.
    Rodenburg, C. J.
    Hendrikse, N. H.
    Bloemendal, H. J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S336 - S336
  • [34] The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain
    Pockett, R. D.
    Castellano, D.
    McEwan, P.
    Oglesby, A.
    Barber, B. L.
    Chung, K.
    EUROPEAN JOURNAL OF CANCER CARE, 2010, 19 (06) : 755 - 760
  • [35] Treatment with zolendronic acid is beneficial before onset of skeletal morbidity in patients with bone metastases from prostate cancer
    Wirth, M. P.
    Schmidt, K.
    Miller, K.
    Eickenberg, H. U.
    Lein, M.
    Haus, U.
    Stockle, M.
    Graefen, M.
    Stenzl, A.
    Effert, P.
    EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 98 - 98
  • [36] A gene expression signature from bone metastases as predictor of clinical outcome in breast cancer patients
    Capulli, M.
    Rucci, N.
    Angelucci, A.
    Martella, F.
    Bologna, M.
    Driouch, K.
    Landemaine, T.
    Lidereau, R.
    Clement-Lacroix, P.
    Garcia, T.
    Teti, A.
    Ricevuto, E.
    CALCIFIED TISSUE INTERNATIONAL, 2007, 80 : S62 - S62
  • [37] Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice
    So, Alan
    Chin, Joseph
    Fleshner, Neil
    Saad, Fred
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2012, 6 (06): : 465 - 470
  • [38] Clinical Experience and Radiation Safety of the First-in-Class Alpha-Pharmaceutical, Alpharadin (radium-223) in Patients with Castration-Resistant Prostate Cancer (CRPC) and Bone Metastases
    Nilsson, S.
    Parker, C.
    Biggin, C.
    Bruland, O.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S375 - S376
  • [39] Zoledronic acid has broad long-term efficacy in reducing skeletal complications in patients with bone metastases from breast cancer, prostate cancer, and other solid tumors
    Coleman, R
    Rosen, L
    Gleason, DM
    Zheng, M
    BONE, 2004, 34 : S84 - S85
  • [40] Ra-223 alpha-Therapy in Patients with Bone Metastases from Castration-resistant Prostate Cancer
    Jessome, Rebecca
    JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES, 2015, 46 (02) : 156 - 161
12345